New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
16:10 EDTHALOHalozyme reports FDA removes clinical hold on Phase 2 study 202
News For HALO From The Last 14 Days
Check below for free stories on HALO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
14:00 EDTHALOBaxter, Halozyme announce favorable FDA panel recommendation on HyQvia
Subscribe for More Information
12:39 EDTHALOFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
Subscribe for More Information
07:10 EDTHALOFDA Blood Products Advisory Committee to hold a meeting
Subscribe for More Information
July 22, 2014
09:04 EDTHALOHalozyme resumes enrollment and dosing of patients for PEGPH20 Phase 2 trial
Halozyme Therapeutics announced that it has resumed enrollment and dosing of patients in its ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer under the revised clinical protocol agreed to with the FDA in June. PEGPH20 is an investigational PEGylated form of Halozyme's proprietary recombinant human hyaluronidase under development for the systemic treatment of tumors that accumulate hyaluronan.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use